Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00730366
Other study ID # DELIMAL
Secondary ID
Status Completed
Phase Phase 3
First received August 5, 2008
Last updated September 12, 2010
Start date March 2004
Est. completion date December 2006

Study information

Verified date September 2010
Source Institute of Tropical Medicine, Belgium
Contact n/a
Is FDA regulated No
Health authority Burkina Faso: Ministry of Health
Study type Interventional

Clinical Trial Summary

Malaria in pregnancy contributes substantially to maternal anaemia and low birth weight: effective malaria control in pregnancy could avoid about 10,000 maternal and up to 200,000 infant deaths every year. Intermittent preventive treatment with the drug sulfadoxine-pyrimethamine (IPTp-SP), administered at least twice during routine antenatal clinics, is recommended by the World Health Organization for areas of moderate to high malaria transmission, including Sub-Saharan Africa.

Studies carried out in Kenya and Malawi before 2004 had showed that two doses of IPTp-SP significantly reduce maternal anaemia, placental malaria parasitaemia and low birth weight. However, in countries where this strategy had been introduced as part of national policy, the coverage of the target population has varied widely, with estimates of 33-93% for uptake of one dose and 24-68% for two doses, and no country had reached the goal of 80% of pregnant women receiving at least 2 doses of IPTp. New approaches designed to improve IPTp coverage were therefore urgently needed.

This study was therefore set up in 2002, in order to evaluate the additional effect of a targeted promotional campaign on antenatal clinics utilization and on coverage and uptake of Intermittent preventive treatment with sulfadoxine-pyrimethamine in a rural health district in Burkina Faso; and to investigate the effectiveness of intermittent preventive treatment with the sulfadoxine-pyrimethamine compared with weekly chloroquine, in order to provide additional evidence to the Burkinabé Ministry of Health for an impending policy change.


Description:

Each year, about 50 million women living in malaria endemic regions become pregnant, more than half in sub-Saharan Africa. In areas of relatively stable transmission, where acquired immunity to Plasmodium falciparum limits infection and prevents severe disease in adults, women in their first and second pregnancy are the most vulnerable subjects, due to a higher risk of severe anaemia and a low birth weight (LBW) outcome, a leading cause of child mortality and poor growth and development.

Malaria in pregnancy and its adverse consequences can be prevented with suppressive antimalarial treatment or chemoprophylaxis. Weekly chloroquine (CQ) had been the basis for prevention for many years, but its application became limited over time, partly because of difficulties in coverage and compliance throughout pregnancy and partly because of increased parasite resistance to CQ in endemic areas. A new strategy for prevention based on insecticide-treated bed nets (ITNs) and use of intermittent preventive treatment in pregnancy (IPTp) was thus formulated, with IPTp being based on the administration of treatment doses of sulfadoxine-pyrimethamine (1500/75 mg; SP) to all pregnant women at pre-defined intervals and regardless of malaria infection. WHO elaborated new recommendations, based on the administration of SP two or three times at scheduled antenatal visits at least one month apart from the second trimester onwards. Evidence of the efficacy of IPTp with SP for preventing malaria infection and improving birth weight was reported from East Africa and West Africa.

However, the IPTp strategy assumes that most pregnant women attend antenatal clinics (ANC) at least twice during their pregnancy and at a time when SP can be administered under direct observation. Unfortunately, it appeared soon that late attendance to ANC and weak health services limit the effectiveness of this strategy; coverage with two or more SP doses varied widely (24-68%) and was well behind the goal of 80% proposed by the Roll Back Malaria Partnership. New approaches to increase IPTp coverage were urgently needed.

This study, conceived in 2002 and carried out between 2004 and 2006, had therefore two different components: on one side, it investigated whether promoting regular and early antenatal attendance of pregnant women through community based health education would increase coverage and uptake of IPTp; on the other side, it investigated the effectiveness of IPTp-SP compared with weekly CQ, in order to provide additional evidence to the Burkinabé Ministry of Health for an impending policy change.


Recruitment information / eligibility

Status Completed
Enrollment 2766
Est. completion date December 2006
Est. primary completion date October 2006
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

- Female

- First or second trimester of pregnancy

- First or second pregnancy

- Resident in the study area

Exclusion Criteria:

- Refuse to give informed consent

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
sulfadoxine-pyrimethamine
Sulfadoxine-pyrimethamine given as intermittent therapy, at the dosage of 1500/75 mg per administration (3 tablets), Twice during pregnancy
Chloroquine
Chloroquine tablets 100 mg. First administration of 1500 mg given over three days, followed by weekly doses of 300 mg/week

Locations

Country Name City State
Burkina Faso District Sanitaire Boromo

Sponsors (5)

Lead Sponsor Collaborator
Institute of Tropical Medicine, Belgium Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Liverpool School of Tropical Medicine, National Laboratory of Public Health,Burkina Faso, University of Ouagadougou, Burkina Faso

Country where clinical trial is conducted

Burkina Faso, 

Outcome

Type Measure Description Time frame Safety issue
Primary Birth weight At delivery No
Secondary Anemia At 32 weeks gestation and at delivery No
Secondary Peripheral and placental parasitaemia At 32 weeks gestation (peripheral) and at delivery (both) No
Secondary Gestational age At first antenatal visit No
See also
  Status Clinical Trial Phase
Completed NCT03508349 - Routine Antenatal Care Versus Screening and Treatment of Malaria in Pregnancy in Rwanda N/A
Completed NCT01053325 - Establishing Effectiveness of Daily Co-trimoxazole Prophylaxis For Prevention of Malaria in Pregnancy Phase 3
Completed NCT00140517 - Relationships Between the Use of Antimalarial Drugs in Pregnancy and Plasmodium Falciparum Resistance N/A
Recruiting NCT05306067 - Plasmodium Falciparum Genomic Intelligence in Mozambique
Recruiting NCT05757167 - Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics Phase 4
Active, not recruiting NCT01555255 - Malaria Rapid Diagnostic Tests (RDTs) in Pregnancy: Detection of Placental Malaria N/A
Completed NCT01136850 - Intermittent Preventive Treatment With Azithromycin-containing Regimens in Pregnant Women in Papua New Guinea Phase 3
Terminated NCT04148690 - Assessing the Impact of Group Antenatal Care on IPTp Uptake in Tanzania N/A
Completed NCT04160026 - Acceptability and Feasibility in the Context of the IMPROVE Trial in Kenya Phase 4
Completed NCT04783051 - Comparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG) Phase 3
Not yet recruiting NCT05348746 - ERASE - Impact of COVID-19 on Malaria Control
Completed NCT03998839 - TIPTOP Sulfadoxine-pyrimethamine (SP) Drug Resistance Study
Completed NCT03208179 - Improving PRegnancy Outcomes With Intermittent preVEntive Treatment in Africa Phase 3
Completed NCT01120145 - Assessment of Sulphadoxine-pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in Malawi N/A
Completed NCT00852423 - Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria Phase 3
Completed NCT00680732 - Prevention of Intrauterine Growth Retardation in Burkina Faso: the Malaria Component Phase 4
Recruiting NCT03754322 - LAMP Detection of Malaria in PREGnancy (LAMPREG) Trial N/A
Not yet recruiting NCT03944317 - Azithromycin (AZ) and Sulphadoxine-pyrimethamine (SP) for Malaria Prevention in Pregnant Women (IPT-AZ/IPT-SP) N/A
Completed NCT05294406 - Intermittent Preventive Treatment With Dihydroartemisinin-piperaquine in Papua, Indonesia Phase 4
Recruiting NCT04825782 - MiMBa Pregnancy Registry